Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  BB Biotech AG    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: BB BIOTECH AG: Vaccines leading -2-

01/22/2021 | 01:07am EST
Thomas Egger, teg@te-communications.ch 
www.bbbiotech.com 
Company profile 
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in 
Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are 
mainly located in the US and Western Europe. 
BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its 
distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of 
Bellevue Asset Management AG when making its investment decisions. 
Disclaimer 
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such 
statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject 
to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and 
its directors and officers accept no responsibility in that regard. All forward-looking statements included in this 
release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation 
to update any forward-looking statements as a result of new information, future events or other factors. 
Composition of BB Biotech's portfolio as of December 31, 2020 
(in % of securities, rounded values) 
Ionis Pharmaceuticals                      10.4% 
Moderna                                     6.7% 
Neurocrine Biosciences                      6.5% 
Argenx SE                                   6.1% 
Incyte                                      5.6% 
 
Vertex Pharmaceuticals                      4.8% 
Alexion Pharmaceuticals                     4.5% 
Arvinas                                     4.1% 
Fate Therapeutics                           4.1% 
Agios Pharmaceuticals                       4.0% 
Halozyme Therapeutics                       3.8% 
Alnylam Pharmaceuticals                     3.4% 
Crispr Therapeutics                         3.1% 
Sage Therapeutics                           3.0% 
Radius Health                               3.0% 
Biogen                                      2.9% 
Myovant Sciences                            2.9% 
Intra-Cellular Therapies                    2.5% 
Macrogenics                                 2.5% 
Scholar Rock Holding                        2.5% 
Esperion Therapeutics                       2.3% 
Generation Bio Co.                          1.5% 
Molecular Templates                         1.3% 
Relay Therapeutics                          1.3% 
Exelixis                                    1.3% 
Mersana Therapeutics                        1.1% 
Nektar Therapeutics                         1.0% 
Black Diamond Therapeutics                  1.0% 
Beam Therapeutics                           0.7% 
Kezar Life Sciences                         0.5% 
Wave Life Sciences                          0.5% 
Homology Medicines                          0.4% 
Voyager Therapeutics                        0.4% 
Cidara Therapeutics                         0.1% 
 
Alder Biopharmaceuticals - CVR              0.1% 
 
Total securities                  CHF 3 954.7 mn 
 
Other assets                          CHF 8.4 mn 
Other payables                     CHF (75.6) mn 
 
Net Asset Value                   CHF 3 887.5 mn 
 ----------------------------------------------------------------------------------------------------------------------- 

2021-01-22 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
              Switzerland 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1162360 
 
End of News   DGAP News Service 
=---------- 

(MORE TO FOLLOW) Dow Jones Newswires

January 22, 2021 01:06 ET (06:06 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
AGIOS PHARMACEUTICALS, INC. 0.15% 47.51 Delayed Quote.9.65%
ALEXION PHARMACEUTICALS, INC. -0.51% 151.97 Delayed Quote.-2.73%
ALNYLAM PHARMACEUTICALS, INC. 0.44% 148.75 Delayed Quote.14.45%
ARGENX SE -2.87% 272.4 Real-time Quote.15.37%
ARVINAS, INC. -1.28% 77.3 Delayed Quote.-8.98%
BB BIOTECH AG 2.25% 86.3 Delayed Quote.16.39%
BEAM THERAPEUTICS INC. 7.24% 95.58 Delayed Quote.17.08%
BIOGEN INC. 0.13% 273.24 Delayed Quote.11.59%
BLACK DIAMOND GROUP LIMITED 3.13% 3.29 Delayed Quote.17.28%
BLACK DIAMOND THERAPEUTICS, INC. -0.25% 27.93 Delayed Quote.-12.85%
CIDARA THERAPEUTICS, INC. 0.88% 2.29 Delayed Quote.14.50%
CRISPR THERAPEUTICS AG 3.63% 130.25 Delayed Quote.-14.93%
ESPERION THERAPEUTICS, INC. 4.13% 28.52 Delayed Quote.9.69%
EXELIXIS, INC. 2.95% 22.3 Delayed Quote.11.11%
FATE THERAPEUTICS, INC. 7.68% 96.61 Delayed Quote.6.25%
HALOZYME THERAPEUTICS, INC. 2.70% 46.47 Delayed Quote.8.80%
HOMOLOGY MEDICINES, INC. 4.84% 11.26 Delayed Quote.-0.27%
INCYTE CORPORATION 1.23% 79.63 Delayed Quote.-9.57%
IONIS PHARMACEUTICALS, INC. 3.15% 54.05 Delayed Quote.-4.40%
KEZAR LIFE SCIENCES, INC. 12.41% 6.16 Delayed Quote.18.01%
MERSANA THERAPEUTICS, INC. 8.80% 19.78 Delayed Quote.-25.67%
MODERNA, INC. 1.67% 157.4 Delayed Quote.50.67%
MOLECULAR TEMPLATES, INC. 5.32% 11.48 Delayed Quote.22.26%
MYOVANT SCIENCES LTD. 6.19% 23.85 Delayed Quote.-13.65%
NEKTAR THERAPEUTICS 4.10% 23.62 Delayed Quote.38.94%
NEUROCRINE BIOSCIENCES, INC. -0.07% 109.43 Delayed Quote.14.17%
RADIUS HEALTH, INC. 1.88% 18.96 Delayed Quote.6.16%
SAGE THERAPEUTICS, INC. 2.68% 87.28 Delayed Quote.0.89%
SCHOLAR ROCK HOLDING CORPORATION 4.99% 56.8 Delayed Quote.17.04%
VERTEX CORPORATION 2.15% 2277 End-of-day quote.26.64%
VERTEX PHARMACEUTICALS -1.02% 210.38 Delayed Quote.-10.98%
VOYAGER THERAPEUTICS, INC. 5.29% 5.97 Delayed Quote.-16.50%
WAVE LIFE SCIENCES LTD. 6.59% 10.03 Delayed Quote.27.45%
All news about BB BIOTECH AG
02/19DGAP-NEWS  : BB Biotech AG pubblica il rapporto annuale 2020
DJ
02/19PRESS RELEASE  : BB Biotech AG publishes its 2020 annual report
DJ
02/19GLOBAL MARKETS LIVE: Novavax, IBM, Swiss Re…
02/19BB BIOTECH  : publishes its 2020 annual report
EQ
02/03WHO-led COVAX vaccine scheme agrees new supply deal with India's Serum
RE
01/22GLOBAL MARKETS LIVE: Honor, Google, Samsung…
01/22BB BIOTECH  : Projects FY20 Profit Growth
MT
01/22DGAP-ADHOC  : BB Biotech AG chiude in utile l'esercizio 2020
DJ
01/22DGAP-NEWS  : BB BIOTECH AG: I vaccini tracciano la -2-
DJ
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
More news
Financials
Sales 2021 0,54 M 0,59 M 0,59 M
Net income 2021 231 M 252 M 252 M
Net cash 2021 73,0 M 79,7 M 79,7 M
P/E ratio 2021 20,7x
Yield 2021 3,81%
Capitalization 4 781 M 5 234 M 5 220 M
EV / Sales 2021 8 710x
EV / Sales 2022 9 791x
Nbr of Employees -
Free-Float 97,2%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 79,50 CHF
Last Close Price 86,30 CHF
Spread / Highest target 5,45%
Spread / Average Target -7,88%
Spread / Lowest Target -21,2%
EPS Revisions
Managers and Directors
NameTitle
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BB BIOTECH AG16.39%5 234
MODERNA, INC.50.67%62 924
LONZA GROUP AG1.20%46 814
IQVIA HOLDINGS INC.8.49%37 278
CELLTRION, INC.-17.13%36 297
SEAGEN INC.-12.90%27 637